CCND1 and cancer: Herein, we used NGS to interrogate the complex genomic landscape of 2457 patients with diverse cancers, of whom 507 patients harbored specific, potentially sensitizing G1/S phase cell-cycle (CDK4/6, CCND1/2/3, or CDKN2A/B) gene alterations.